Veregen

(Sinecatechins)

Phase 2Small molecule

IIstituto Clinico Humanitas

Veregen is one of 25 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Veregen

IIstituto Clinico Humanitas

Phase 2

1 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 9

Prednisone/prednisolone

Roche

Preclinical

3 10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 2Active, not recruiting

Prostate Cancer

NCT04597359

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04597359·360 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 31, 2006

VEREGEN

NDA NDA021902

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sinecatechins. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sinecatechins compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sinecatechins. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021902). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Veregen. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Istituto Clinico Humanitas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIstituto Clinico Humanitas

Patent Landscape[5]

Patent Cliff

Oct 2, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7858662Oct 2, 2026

Veregen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Prostate Cancer1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News